Showing results (1-10 of 471) with videos related to
Sort By:
Pageof 48
Controlled Clinical Trials|December 31, 1997
Developing systems for cost-effective auditing of clinical trialsR M Califf, S L Karnash, L H WoodliefJournal of the American College of Cardiology|December 1, 1995
Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trialS L Karnash, C B Granger, H D White, et al.Circulation|January 15, 1995
Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarctionC L Grines, E J Topol, W W O'Neill, et al.JAMA|February 12, 1998
Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary ArteriesW R Hathaway, E D Peterson, G S Wagner, et al.Circulation|December 1, 1994
Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesN S Kleiman, H D White, E M Ohman, et al.Circulation|March 15, 1995
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I InvestigatorsK L Lee, L H Woodlief, E J Topol, et al.Journal of the American College of Cardiology|February 1, 1997
Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesB E Tardiff, R M Califf, D Morris, et al.Circulation|May 1, 1993
Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Analysis of determinants of improvement. The TAMI Study GroupJ K Harrison, R M Califf, L H Woodlief, et al.The American Journal of Cardiology|November 11, 1998
A perspective on the regulation of the evaluation of new antithrombotic drugsR M CaliffPageof 48